Mindpeak, a Hamburg, Germany-based company which specializes in AI-powered pathological solutions, raised $15.3M in Series A funding.
The round was led by ZEISS Ventures and InnoVentureFund with participation from AI.FUND, the European Innovation Council Fund, and others.
The company intends to use the funds to further enhance its product development roadmap for AI-powered histopathological assessments, supporting clinical labs and biopharma companies worldwide.
Led by CEO Felix Faber, Mindpeak is an innovator in AI-driven digital pathology solutions. The company develops algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Its platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care.
The company’s solutions enable automated histological and immunohistochemical tissue analysis, helping experts make more confident decisions. To date, over 30,000 patient diagnoses have been supported using the AI solution. Biopharmaceutical companies also use this AI technology to predict the effectiveness of certain medications in cancer therapy and to enable targeted treatments.
Recently, Mindpeak expanded its product portfolio to include additional organs, biomarkers, and stainings.
FinSMEs
30/09/2024